secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009782
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025
-----------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.
- Figure is a management estimate subject to completion of financial closing procedures; no audit or review by independent accountants.
- Company also presented at J.P. Morgan Healthcare Conference on January 12, 2026; presentation content was not detailed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526009782/0001193125-26-009782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526009782/dyn-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer